Cannabis REITs and Lenders: The Quiet Winners of Schedule III

Why the Smart Money Is Looking Beyond Plant-Touching Stocks

When the DOJ moved medical marijuana to Schedule III on April 23, the market reaction was predictable: shares of multi-state operators like Curaleaf, Green Thumb Industries, and Trulieve surged. Penny stocks spiked. Cannabis ETFs had their best week in years.

But while the headlines focused on plant-touching companies, a quieter group of cannabis-adjacent investments was also climbing — and some analysts believe these ancillary plays offer a more compelling risk-reward profile in the post-rescheduling landscape.

Cannabis real estate investment trusts and specialty lenders have been steadily building positions in the legal cannabis industry for years, and they stand to benefit enormously from the regulatory shift without carrying the direct operational and legal risks that plant-touching companies face.

The REIT Advantage

Innovative Industrial Properties (IIPR)

Innovative Industrial Properties has been the dominant cannabis REIT since its founding in 2016. The company's model is straightforward: it buys properties, leases them back to cannabis operators on long-term triple-net leases, and collects rent. As of early 2026, IIPR owned over 100 properties across 19 states.

The Schedule III reclassification benefits IIPR in several ways. First, its tenants — licensed medical cannabis operators — will now be able to deduct their rent as a business expense under the 280E relief, which improves their financial health and reduces IIPR's tenant default risk. Second, the regulatory de-risking makes it easier for IIPR to access traditional capital markets at lower borrowing costs. Third, the potential expansion of the medical cannabis market means more operators will need facilities, expanding IIPR's addressable market.

IIPR currently offers a dividend yield that significantly exceeds the REIT sector average, making it attractive to income-focused investors.

Why REITs Reduce Risk

The fundamental appeal of cannabis REITs is that they are one step removed from the plant itself. IIPR does not grow, process, or sell cannabis. It owns buildings. This distinction matters enormously for regulatory risk. Even if federal enforcement were to intensify — an unlikely but not impossible scenario — IIPR's properties are simply commercial real estate. The company has always been able to access U.S. stock exchanges, traditional banking, and institutional capital in ways that plant-touching companies could not.

The Lending Play

Chicago Atlantic Real Estate Finance (REFI)

Chicago Atlantic has carved out a niche as one of the premier lenders to the cannabis industry. The company provides mortgage loans, construction financing, and working capital lines to licensed cannabis operators. Its loans are secured by real estate and business assets, and its portfolio has been performing well despite the broader industry's financial struggles.

Schedule III reclassification improves Chicago Atlantic's position by strengthening its borrowers' cash flows through 280E relief. Companies that were barely meeting debt service obligations under punitive tax rates will suddenly have significantly more free cash flow, reducing the risk of loan defaults.

NewLake Capital Partners (NLCP)

NewLake operates a model similar to IIPR, providing sale-leaseback financing to cannabis operators. The company has been expanding its portfolio and benefits from the same tailwinds affecting the broader cannabis REIT space.

The Banking Pathway

Perhaps the most significant long-term implication of Schedule III for cannabis lenders is the potential opening of traditional banking channels. While rescheduling does not fully resolve the federal banking question, it reduces the perceived risk for financial institutions considering cannabis-related services. Several regional banks have already announced expanded cannabis banking programs in the week following the reclassification.

If the SAFE Banking Act — or similar legislation — passes in the current congressional session, the lending landscape could transform rapidly. Companies like Chicago Atlantic that built expertise in cannabis lending during the prohibition era would be well-positioned to compete with, or be acquired by, larger financial institutions entering the space.

Comparing Plant-Touching vs. Ancillary Investments

Volatility and Risk

Plant-touching cannabis stocks have historically been among the most volatile equities in the market. Companies like Tilray, Canopy Growth, and even the stronger MSOs have experienced drawdowns of 80 percent or more from their peaks. Penny stocks in the space regularly see triple-digit percentage swings on news events, as the recent Akanda spike demonstrated.

Cannabis REITs and lenders, by contrast, have traded with lower volatility. Their revenue is based on contractual lease payments and loan interest — predictable cash flows that provide a floor for valuation. They also pay dividends, which plant-touching companies generally do not.

Growth Potential

The counterargument is that ancillary plays may have less upside in a full legalization scenario. If marijuana is eventually descheduled and interstate commerce is permitted, the largest MSOs could become national brands worth tens of billions. REITs and lenders would benefit from that growth, but their upside is inherently capped by the contractual nature of their revenue.

The Balanced Approach

Many cannabis-focused fund managers advocate a blended approach: core holdings in financially strong MSOs supplemented by positions in REITs and lenders for income and stability. The post-Schedule III environment makes this strategy more accessible because both categories of investment are now on stronger regulatory footing.

Risks to Consider

No investment thesis is without risk. Cannabis REITs face concentration risk — their tenant base is limited to the cannabis industry, and a severe market downturn could lead to widespread tenant defaults. Lenders face credit risk in an industry where many operators have weak balance sheets and limited track records.

There is also the political risk of reversal. While Schedule III reclassification appears durable, the broader rescheduling process for recreational marijuana could stall at the June hearing, and state-level repeal movements in Arizona and Massachusetts could shrink certain markets.

Finally, if full legalization and interstate commerce eventually arrive, the current cannabis real estate model — which benefits from supply constraints and geographic limitations — could face disruption. Properties in high-cost states might lose value if operators can source product from lower-cost jurisdictions.

The Investment Landscape Going Forward

The April 23 rescheduling did not just change the law — it changed the investability of cannabis. Institutional investors who previously avoided the sector due to Schedule I concerns are now reconsidering. Insurance companies, pension funds, and endowments that could not touch cannabis-related investments under their compliance frameworks are reviewing whether Schedule III opens the door.

For retail investors, the message is nuanced. The cannabis industry is healthier and more accessible than it has ever been, but it remains a sector with significant risks. REITs and lenders offer a way to participate in the industry's growth while managing some of that risk — and in a post-Schedule III world, that combination may be exactly what the market is looking for.

Staying informed on the companies shaping cannabis access starts local — find a dispensary near you to see the operators that investment capital is backing in your market.